Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: J Heart Lung Transplant. 2016 Jan 15;35(6):714–721. doi: 10.1016/j.healun.2016.01.016

Figure 3.

Figure 3

Calibration histograms in each of derivation (D) and validation (V) cohorts are shown with one-year predicted SHFM mortality risk in each of the derivation cohort (grey bar) and validation cohort (pink bar). Observed composite one-year outcome of mortality, cardiac transplantation or ventricular assist device implantation in each of the derivation cohort (black bar) and validation cohort (red bar). Patients are stratified within the pre-specified categories of clinically relevant one-year risk [low (≤2.5%), intermediate (2.5–≤10%), and high risk (>10%)] according to SHFM-predicted probabilities and subsequently according to BNP levels above (↑) or below (↓) the optimal partition-value (700 pg/ml) based on ROC-analysis in the derivation cohort.